SCHEMBL15974641

SCHEMBL15974641

COC(=O)C(N)C1CCC(C)CC1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.40
CA14 Q9ULX7 1/20 0.36
THRB P10828 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
ALOX5 P09917 1/20 0.34
EPHX1 P07099 2/20 0.34
SLC6A3 Q01959 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28457899 1.00 POLB (0.40) POLBCA14THRBSMN1; SMN2ALOX5
SCHEMBL30039168 1.00 POLB (0.40) POLBCA14THRBSMN1; SMN2ALOX5
SCHEMBL1631394 0.92
SCHEMBL7904677 0.92 CA14 (0.41) POLBCA14THRBSMN1; SMN2ALOX5
SCHEMBL1631397 0.92
SCHEMBL1694458 0.92
Hydrochloric Acid SCHEMBL3838599 0.90 CA14 (0.40) CA14THRBSMN1; SMN2ALOX5SLC6A3
Hydrochloric Acid SCHEMBL17389174 0.90 CA14 (0.40) CA14THRBSMN1; SMN2ALOX5SLC6A3
SCHEMBL21579732 0.84 DPP4 (0.41) CA14THRBSMN1; SMN2ALOX5SLC6A3
SCHEMBL13209988 0.84 DPP4 (0.41) CA14THRBSMN1; SMN2ALOX5SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
US-10421727-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2019-09-24 US disclosed
US-10421727-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2019-09-24 US disclosed
EP-3461816-A1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2019-04-03 EP disclosed
EP-3461816-A1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2019-04-03 EP disclosed
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED 2017-12-28 US disclosed
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED 2017-12-28 US disclosed
US-9840471-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2017-12-12 US disclosed
US-9840471-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2017-12-12 US disclosed
US-9840471-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2017-12-12 US disclosed
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2015-12-31 US disclosed
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2015-12-31 US disclosed
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2015-12-31 US disclosed
EP-2958897-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2015-12-30 EP disclosed
WO-2014130582-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. (US) 2014-08-28 WO disclosed
WO-2014130582-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. (US) 2014-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421727-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 POLB 4409/4885CA14 1215/4885THRB 1203/4885
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 POLB 4409/4885CA14 1215/4885THRB 1203/4885
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 POLB 4409/4885CA14 1215/4885THRB 1203/4885
US-11028052-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 POLB 4409/4885CA14 1215/4885THRB 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.